March 2026: Navigating Marijuana Rescheduling Challenges

The March 2026 Status Report: Executive Intent vs. Administrative Friction

As of March 17, 2026, the administrative machinery is grinding heavily against the entrenched realities of the Controlled Substances Act (CSA). The federal landscape is defined by a profound structural volatility as the United States navigates a historic transition, attempting to move marijuana from Schedule I to Schedule III. While this represents the most significant shift in federal drug policy in over five decades—aiming to harmonize federal law with a maturing state-level market—the process has entered a period of intense administrative ossification.

The primary conflict lies between executive mandate and administrative reality. On December 18, 2025, the President issued the Executive Order “Increasing Medical Marijuana and Cannabidiol Research,” directing the Attorney General to expedite the reclassification process. However, the legal reality as of today remains unchanged: marijuana is a Schedule I substance. This “expeditious” mandate has already met significant resistance under the watch of Attorney General Pam Bondi. Most notably, the Department of Justice (DOJ) missed a critical January 16, 2026, congressional deadline to issue guidelines for easing barriers to Schedule I research. This failure to meet mandated timelines, overseen by Bondi, has fueled deep skepticism among industry stakeholders who view the administration’s rhetoric as increasingly disconnected from the rigid requirements of the Administrative Procedure Act (APA).

Federal Rescheduling Milestones

Procedural Milestone	Actual or Projected Date	Status as of March 17, 2026
HHS Recommendation (Schedule III)	August 2023	Completed
Publication of Notice of Proposed Rulemaking	May 21, 2024	Completed (43,000+ comments)
Confirmation of DEA Administrator Terry Cole	July 22, 2025	Completed
Executive Order to Expedite Rescheduling	December 18, 2025	Issued
Congressional Deadline for Research Guidelines	January 16, 2026	Missed by DOJ (Pam Bondi)
Expected Movement Toward Final Rule	Mid-to-Late 2026	Uncertain due to litigation

While the DOJ struggles with its “expedite” instructions, the primary bottleneck for the rescheduling project remains the leadership and procedural stasis at the Drug Enforcement Administration (DEA).

The DEA Leadership Vacuum and Procedural Stasis

The Drug Enforcement Administration serves as the ultimate gatekeeper for the federal rescheduling project. Despite intense pressure from the White House, the agency’s internal rulemaking has effectively stalled due to a combination of political caution and administrative voids.

The appointment of Terrance “Terry” Cole as DEA Administrator was intended to provide a steady hand for this transition. A 20-year veteran of the agency, Cole was confirmed on July 22, 2025, by a razor-thin 50-48 Senate margin. During his May 2025 confirmation hearing, Cole signaled a shift in agency posture, adopting a “science-first” position. While pledging to prioritize the review of the stalled rescheduling process, he notably stopped short of endorsing reclassification itself, citing a need for further study. This cautious stance acts as a strategic hedge, allowing the DEA to move at a deliberate pace despite the President’s “expeditious” mandate.

Adding to this leadership caution is a literal “procedural vacuum.” In January 2025, administrative proceedings were stayed following an interlocutory appeal regarding the neutrality of DEA leadership. That stay remains active. Complicating matters further is the retirement of the Administrative Law Judge (ALJ) originally tasked with overseeing the hearing process. Without a presiding judge or a briefing schedule to resolve ongoing appeals, the DEA is in a state of administrative paralysis. This deadlock suggests that a final rule is unlikely to emerge until these procedural voids are filled, leaving massive financial stakes hanging in the balance.

The $1.6 Billion Tax Conflict: Section 280E and the “Tax Gambit”

The strategic economic core of rescheduling is the potential demise of Internal Revenue Code (IRC) Section 280E. This provision currently bars cannabis businesses from deducting ordinary operating expenses from their federal taxes, often resulting in effective tax rates as high as 70% to 90%. For an industry operating in a maturing market, the removal of this burden is the single most watched financial event in history.

In anticipation of reform, major Multi-State Operators (MSOs) have engaged in an aggressive “tax gambit,” filing amended returns to claim hundreds of millions in refunds. They argue that 280E should no longer apply to state-legal operations. However, the IRS has maintained a firm resistance, asserting in March 2026 filings that 280E remains constitutional and fully applicable until a final rescheduling rule is formally adopted.

The financial exposure of the industry is staggering:

• Trulieve Cannabis Corp.: Reports an “uncertain tax position” of $630 million related to its 280E challenges as of March 2026.
• The Cannabist Company: Forced into an extended forbearance agreement with senior noteholders as of March 17, 2026, highlighting the liquidity crisis.
• Industry-Wide Total: Estimated outstanding liability and aggressive refund claims exceed $1.6 billion.

This conflict highlights a striking paradox: the industry is paying “prohibition-era” interest rates while simultaneously claiming “reform-era” tax treatment. Trulieve’s recent closing of $60 million in senior secured notes at a 10.5% interest rate serves as a stark “risk premium.” Institutional investors still demand high yields because, until a final rule is adopted, the draconian 280E framework remains the law of the land.

Financial markets are not the only ones recalibrating; federal researchers are also tempering their optimism as the legal complexities of reform become clearer.

Shifting Perspectives: CRS Updates and International Treaty Compliance

The Congressional Research Service (CRS) plays a vital role in shaping legislative expectations. In a significant update published on March 17, 2026, the CRS signaled a newfound caution regarding the inevitability of federal reform.

A critical semantic shift occurred in this latest report: the CRS removed previous language describing rescheduling as “likely,” stating instead that the DOJ “may” move marijuana to Schedule III. This change reflects the growing realization of the procedural hurdles and the high probability of judicial intervention.

One of the most complex hurdles is the “Treaty Compliance Dilemma” involving the 1961 Single Convention on Narcotic Drugs. While some advocates suggest the Attorney General could use the 21 U.S.C. 811(d)(1) pathway to schedule drugs via an expedited process to satisfy treaty obligations, legal experts warn this is “legally perilous.” Bypassing the standard notice-and-comment rulemaking process would almost certainly trigger immediate litigation from prohibitionist groups, as it would be viewed as a departure from established administrative law. This regulatory uncertainty also extends to the hemp industry, where a looming “regulatory cliff” threatens to erase the distinction between hemp and marijuana.

The Hemp-Marijuana Convergence: The 2026 Farm Bill and the “Total THC” Standard

The regulatory boundary between the marijuana market and the hemp-derived cannabinoid industry is reaching a tipping point. As the 2026 Farm Bill moves through committee, federal lawmakers are attempting to close loopholes that have allowed hemp-derived THC products to proliferate. The primary mechanism for this is a transition from “Delta-9” to a “Total THC” standard, which includes THCA.

Hemp Regulatory Comparison

Regulation Detail	Current Standard (2018 Farm Bill)	Proposed 2026 Standard	Implementation
THC Measurement	0.3% Delta-9 THC	0.3% Total THC (inc. THCA)	November 2026
Container Limits	No federal limit	0.4mg per container limit	November 2026
Seed Restrictions	Negligible THC	Restricts seeds from plants >0.3%	November 2026

The CRS has issued a blunt warning regarding these restrictions, characterizing a potential hemp ban as “unenforceable.” Given the lack of FDA and DEA resources, federal researchers anticipate a “hands-off” enforcement environment. While federal agencies remain resource-constrained, the “on-the-ground” reality is being aggressively shaped by state-level enforcement and licensing.

State-Level Maturity: Minnesota’s Transition and Local Control Dynamics

While federal rescheduling remains in administrative limbo, states like Minnesota are aggressively refining their own frameworks. Minnesota is currently in a critical “enforcement phase,” moving toward a comprehensive adult-use market managed by the Office of Cannabis Management (OCM).

The OCM is currently on a statewide listening tour, which included a high-profile stop in Duluth on March 13 to engage local stakeholders. However, small businesses face a “hard cutoff” on March 31, 2026, by which time all hemp edible manufacturers must obtain full OCM licensure or cease operations. This transition is further complicated by an “in-state testing bottleneck,” as new requirements for local laboratory verification have slowed the speed at which products reach shelves.

Case Study: Lakeville, MN Local Control

The city of Lakeville illustrates the power of municipal authority in this maturing market. Their specific licensing features include:

• License Cap: A strict maximum of six cannabis retail operations.
• Zoning Buffer: Stores must be at least 500 feet from schools.
• Processing: Applications are handled on a “First-come, first-served” basis.
• Fees: A mandatory Registration Fee is paid upon application.
• Management: A designated on-site manager is required for all operations.

This maturation is regional; Virginia is targeting a 2027 launch, and Pennsylvania is considering a Cannabis Control Board to oversee both medical and intoxicating hemp markets.

7. Beyond Regulation: The Social Gap and Scientific Barriers

Despite the commercial promise of Schedule III, rescheduling is a limited tool for social and scientific reform. At a March 17, 2026, SXSW panel titled “Why We Have Cannabis Prisoners in 2026,” representatives from the Last Prisoner Project emphasized that Schedule III provides no retroactive relief. It is a “commercial advancement” that does not mandate the release of those currently incarcerated or provide expungement for past offenses.

Furthermore, the DOJ’s failure to issue research guidelines continues to cause “research harm,” stalling scientific advancement even as new data highlights the plant’s therapeutic potential.

Scientific Findings & Research Horizons

Research Topic	Key Finding
Crime Reduction	Medical legalization reduces property crime; recreational reduces violent crime.
Sexual Health	Consistent association with enhanced female orgasmic function.
Opioid Use	Opioid use drops significantly in states with legalized recreational cannabis.
Chronic Pain	Millions of Americans now use CBD as a substitute for traditional painkillers.

8. The Workforce Reality: Employment Policies in a Pre-Rescheduling Era

For the average worker, federal rescheduling does not equate to a change in workplace drug policy. Both the HHS and DOT clarified in March 2026 that marijuana remains Schedule I for federal workplace standards until a final rule is effective.

HHS confirmed on March 16 that “authorized drug testing panels” and “required report nomenclature” remain in full effect. Federal employees and safety-sensitive transportation workers remain subject to metabolite testing. Even after rescheduling, employers will likely retain the right to maintain drug-free workplace policies, especially in roles involving national security.

The overarching theme of 2026 is a conflict between transition and stability. While the executive branch has signaled intent, the administrative and economic friction ensures that the path to a final rule remains a multi-year process. For now, the nation remains in a state of regulatory flux.